Cushing's Syndrome malady

NINDS: Cushing's syndrome, also called , is a rare endocrine disorder caused by chronic exposure of the body's tissues to excess levels of cortisol - a hormone naturally produced by the adrenal gland. Exposure to too much cortisol can occur from long-term use of synthetic glucocorticoid hormones to treat inflammatory illnesses. Pituitary adenomas (benign tumors of the pituitary gland) that secrete increased amounts of ACTH ( a substance that controls the release of cortisol) can also spur overproduction of cortisol. Tumors of the adrenal gland and ectopic ACTH syndrome (a condition in which ACTH is produced by various types of potentially malignant tumors that occur in different parts of the body) can cause similar problems with cortisol balance. Common symptoms of Cushing's syndrome include upper body obesity, severe fatigue and muscle weakness, high blood pressure, backache, elevated blood sugar, easy bruising, and bluish-red stretch marks on the skin. In women, there may be increased growth of facial and body hair, and menstrual periods may become irregular or stop completely. Neurological symptoms include difficulties with memory and neuromuscular disorders.³¹

MalaCards: Cushing's Syndrome, also known as cushing syndrome, is related to pituitary-dependent cushing's disease and petrositis. An important gene associated with Cushing's Syndrome is GIPR (gastric inhibitory polypeptide receptor), and among its related pathways are G alpha (s) signalling events and Breast Cancer Regulation by Stathmin1. The drugs fludrocortisone and fludrocortisone acetate and the compounds cyclophosphamide and naloxone have been mentioned in the context of this disorder. Affiliated tissues include whole blood, thymus and cortex, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

Disease Ontology: An adrenal gland hyperfunction that is caused by overactivity of the adrenal cortex caused by a tumor of the pituitary gland.⁶

NIH Rare Diseases: Cushing's syndrome is an endocrine disorder caused by prolonged exposure of the body's tissues to high levels of cortisol, a hormone produced by the adrenal gland. Excess cortisol may be the result of long-term use of corticosteroid medications or tumors in the pituitary or adrenal glands. Symptoms of Cushing's syndrome include obesity, fatigue, muscle weakness, high blood pressure, high blood sugar, easy bruising and stretch marks. Treatment depends on the underlying cause, but may include decreasing the dosage of corticosteroids or removing the causative tumor.³⁰

MedlinePlus: Cushings syndrome is caused by long-term exposure to too much cortisol, a hormone that your adrenal gland makes. sometimes, taking synthetic hormone medicine to treat an inflammatory disease leads to cushing's. some kinds of tumors secrete a hormone that can cause your body to make too much cortisol. cushing's syndrome is rare. some symptoms are upper body obesity thin arms and legs severe fatigue and muscle weakness high blood pressure high blood sugar easy bruising your treatment will depend on why you have too much cortisol. if it is because you have been taking synthetic hormones, a lower dose may control your symptoms. if a tumor caused it, surgery and other therapies may be needed. most of the time, cushing's syndrome can be cured. nih: national institute of neurological disorders and stroke²³

Genetics Home Reference: Cushing disease is caused by elevated levels of a hormone called cortisol, which leads to a wide variety of signs and symptoms. This condition usually occurs in adults between the ages of 20 and 50; however, children may also be affected. The first sign of this condition is usually weight gain around the trunk and in the face. Affected individuals may get stretch marks (striae) on their thighs and abdomen and bruise easily. Individuals with Cushing disease can develop a hump on their upper back caused by abnormal deposits of fat. People with this condition can have muscle weakness, severe tiredness, and progressively thin and brittle bones that are prone to fracture (osteoporosis). They also have a weakened immune system and are at an increased risk of infections. Cushing disease can cause mood disorders such as anxiety, irritability, and depression. This condition can also affect a person's concentration and memory. People with Cushing disease have an increased chance of developing high blood pressure (hypertension) and diabetes. Women with Cushing disease may experience irregular menstruation and have excessive hair growth (hirsutism) on their face, abdomen, and legs. Men with Cushing disease may have erectile dysfunction. Children with Cushing disease typically experience slow growth.¹⁷

Wikipedia: Cushing\'s syndrome describes the signs and symptoms associated with prolonged exposure to...⁴⁴ more...

Aliases & Descriptions:

cushing's syndrome 6 30 17 31 23 cushing syndrome 30 8 32 43 hypercortisolism 30 17 adrenal hyperfunction resulting from pituitary acth excess 30 ectopic adrenocorticotropic hormone syndrome 30 nodular primary adrenocortical dysplasia 30 pituitary-dependent cushing's disease 43 pituitary-dependant hypercortisolism 17 pituitary-dependant cushing syndrome 17 pituitary acth hypersecretion 17

adrenal gland hyperfunction 43 pituitary cushing syndrome 17 suprarenogenic syndrome 6 adrenal cortex adenoma 30 pituitary basophilism 6 ectopic acth syndrome 30 acth syndrome ectopic 32 hyperadrenocorticism 30 cushing disease 17

Diseases related to cushing's syndrome by text searches and GeneDecks gene sharing:

(show top 50)    (show all 971)

id	Related Disease	Score	Top Affiliating Genes
1	pituitary-dependent cushing's disease	35.7	GH1, SST, NR3C1, CRH, PRL, POMC
2	petrositis	35.3	IGF1, GH1, CRH, PRL, POMC
3	adrenocortical hyperplasia	33.9	PDE11A, MC2R, IGF2, GNAS, HSD3B1, CYP11B2
4	adrenal adenoma	33.8	REN, CHGA, MKI67, INHA, MEN1, MC2R
5	adrenal hyperplasia	32.6	PDE11A, REN, CNC, GCG, SERPINA7, LEP
6	gastrinoma	32.2	GCG, CHGA, INS, MEN1, ENO2, IGF1
7	adrenal gland hyperfunction	31.8	INS, HSD11B2, HSD3B1, PRL
8	neuroendocrine tumor	31.3	RET, GCG, CHGA, MKI67, MEN1, ENO2
9	multiple endocrine neoplasia	30.7	RET, CNC, GCG, PBX1, CHGA, CDKN1B
10	orthostatic hypotension	30.7	REN, CHGA, GNAS, CALCA, SST, POMC
11	acth deficiency	30.6	HSD11B1, GH1, TRH, NR3C2, CRH, PRL
12	hypokalemia	30.5	REN, AVPR2, INS, HSD11B2, HSD17B6, CYP11B2
13	21-hydroxylase deficiency	30.5	INHA, CYP21A2, SYP
14	conn's syndrome	30.5	REN, INHA, CYP11B2, NR3C2, AGTR2
15	adrenal carcinoma	30.3	LEP, MKI67, ENO2, CYP17A1, CRH, SYP
16	neuroendocrine carcinoma	30.3	GCG, CHGA, MUC1, S100B, FHIT, MEN1
17	esthesioneuroblastoma	30.2	S100B, ENO2, SST, SYP
18	empty sella syndrome	30.2	IGF1, GH1, PRL
19	adrenocortical carcinoma	30.1	CHGA, MKI67, INHA, MC2R, IGF2, HSD11B2
20	primary pigmented nodular adrenocortical disease	30.0	PDE11A, CNC, CHGA, GNAS, CYP19A1, NR3C1
21	pituitary tumor	29.8	CNC, PBX1, CHGA, CDKN1B, MEN1, IGF1
22	tumors of adrenal cortex	29.6	PDE11A, LHCGR, MKI67, MC2R, TP53, CYP11B1
23	autoimmune thyroiditis	29.6	RET, SERPINA7, IL2RA, CALCA, GHRL, HLA-B
24	carcinoid tumors	29.5	RET, PCNA, GCG, BCL2, CHGA, MUC1
25	immunodeficiency	29.5	CEACAM1, INHA, INS, IL18, IL2RA, IL6
26	small cell carcinoma	29.5	PCNA, BCL2, CHGA, MUC1, BAX, AVPR1B
27	ganglioneuroblastoma	29.4	CHGA, S100B, ENO2, TP53, SST, CRH
28	diabetes insipidus	29.3	REN, VWF, S100B, CGA, AVPR1B, AVPR2
29	adrenal cortical carcinoma	29.3	MUC1, S100B, HSD11B2, TP53
30	carney complex	29.1	PDE11A, CNC, CHGA, CDKN1B, MEN1, GNAS
31	adrenocortical tumor	28.9	PDE11A, RET, CNC, LHCGR, CHGA, MKI67
32	leiomyomatosis	28.8	LHCGR, INHA, FH, GNRH1, PGR
33	meningioma	28.7	PCNA, MKI67, PGR
34	virilization	28.6	LHCGR, LEP, CGA, INS, MC2R, IGF2
35	zollinger-ellison syndrome	28.4	CHGA, MEN1, IL6, IL8, GHRH, SST
36	pheochromocytoma	28.0	REN, RET, SERPINE1, BCL2, LEP, CHGA
37	pancreatic endocrine tumors	28.0	GCG, BCL2, CHGA, CEACAM1, CDKN1B, MKI67
38	hypercalcemia	27.7	BGLAP, CHGA, AVPR2, CD36, MEN1, IL6
39	metabolic syndrome x	27.7	SERPINE1, LPL, LEP, INS, IL6, IGFBP1
40	hyperprolactinemia	27.6	BGLAP, CGA, INS, IL6, IGFBP3, IGF1
41	sinusitis	27.5	VWF, PCNA, SERPINE1, BGLAP, MUC1, BAX
42	lipodystrophy	27.3	RETN, SERPINE1, LPL, LEP, INS, IL18
43	diarrhea	27.2	REN, VWF, GCG, CHGA, INS, FGF19
44	mediastinitis	27.1	PCNA, CGA, IL2RA, IL6, ENO2, CALCA
45	sarcoidosis	26.8	IL18, IL1RN, IL2RA, IL6, IL8, IGF1
46	acromegaly	26.6	RETN, CNC, GCG, SERPINE1, LPL, PBX1
47	arthritis	26.5	IL6, IL8, TNFSF11, NR4A2
48	myxoma	26.4	CNC, KITLG, BCL2, MUC1, S100B, CD36
49	hepatoblastoma	26.2	KITLG, PCNA, SERPINA7, SERPINA6, SERPINE1, BCL2
50	aldosteronism	26.0	REN, RETN, SERPINA6, SERPINE1, LHCGR, CHGA

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 aminoglutethimide, fludrocortisone, fludrocortisone acetate, mitotane

MalaCards organs/tissues related to cushing's syndrome:

²²

MGI Mouse Phenotypes related to cushing's syndrome:

²⁵ (show all 28)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.6	POR, PRKAR1A, CRH, SP3, CALCA, LPL
2	endocrine/exocrine gland phenotype	MP:0005379	10.3	GHR, GHRH, TRH, CYP11B2, CYP11B1, NR5A1
3	craniofacial phenotype	MP:0005382	9.6	POR, PRKAR1A, TFPI, SP3, SP1, GNAS
4	normal phenotype	MP:0002873	9.5	SST, NR3C1, NR5A1, CRH, AGRP, SYP
5	embryogenesis phenotype	MP:0005380	9.4	TFPI, PRKAR1A, PRL, POR, PGR, NR5A1
6	limbs/digits/tail phenotype	MP:0005371	9.0	GHR, TNFRSF11B, TNFSF11, SP1, TFPI, POR
7	hematopoietic system phenotype	MP:0005397	8.8	IGF2, TNFSF11, PRKAR1A, FHIT, INHA, AVPR2
8	no phenotypic analysis	MP:0003012	8.7	GHRL, GHSR, TP53, SST, NR2F1, AGRP
9	reproductive system phenotype	MP:0005389	8.5	REN, RET, PBX1, LHCGR, LEP, CGA
10	pigmentation phenotype	MP:0001186	8.4	PRKAR1A, NR2F1, CYP19A1, TP53, CASP3, CDKN1B
11	renal/urinary system phenotype	MP:0005367	8.1	REN, RET, AGTR2, PRKAA2, POR, ADM
12	liver/biliary system phenotype	MP:0005370	8.1	IGFBP1, F9, HSD11B1, GH1, GHR, GHRH
13	hearing/vestibular/ear phenotype	MP:0005377	8.1	CALCA, TNFRSF11B, CYP19A1, NR2F1, PLAT, TSHR
14	nervous system phenotype	MP:0003631	7.9	PBX1, BAX, CGA, AVPR1B, CD36, CDKN1B
15	immune system phenotype	MP:0005387	7.1	CRH, PLAT, TSHR, TFPI, PRKAR1A, PRL
16	skeleton phenotype	MP:0005390	7.0	CYP19A1, TNFSF11, TNFRSF11B, TP53, GHSR, SP1
17	integument phenotype	MP:0010771	6.9	PTGS1, CYP19A1, SP1, SP3, NR3C1, CRH
18	digestive/alimentary phenotype	MP:0005381	6.6	FHIT, MEN1, IL18, IGF2, GNRH1, HSD11B2
19	tumorigenesis	MP:0002006	6.6	AIP, TP53, PTGS1, NR0B1, AGTR2, PRKAR1A
20	behavior/neurological phenotype	MP:0005386	6.4	NR5A1, CRHBP, PLAT, NOS3, AGRP, AGTR2
21	adipose tissue phenotype	MP:0005375	6.3	IL18, IL6, MC2R, MC3R, IGFBP3, IGF1
22	vision/eye phenotype	MP:0005391	5.9	TP53, SP1, SP3, NR2F1, PLAT, NOS3
23	muscle phenotype	MP:0005369	5.5	NOS3, PLAT, CYP19A1, CYP11A1, CYP11B2, PTGS1
24	mortality/aging	MP:0010768	5.3	REN, RET, KITLG, VWF, GCG, SERPINE1
25	growth/size phenotype	MP:0005378	4.5	LHCGR, LEP, CHGA, BAX, CGA, AVPR2
26	cardiovascular system phenotype	MP:0005385	4.4	IL1RN, IL6, MC2R, IGF2, IGF1, F9
27	cellular phenotype	MP:0005384	3.8	SLPI, PGR, ADM, ADIPOQ, POMC, RET
28	homeostasis/metabolism phenotype	MP:0005376	1.3	PRKAA2, PRKAR1A, PRL, PRKAB1, POR, POMC

Articles related to cushing's syndrome:

(show top 50)    (show all 331)

id	Title	Authors	Year	Affiliating Genes
1	New insight into the hypercoagulability of Cushing's syndrome. (21304226)	Daidone V.... Casonato A.	2011	VWF
2	Cushing syndrome in a young woman due to primary pigm ented nodular adrenal disease. (19703806)	Hackman K.L.... Topliss D.J.	2010	POMC
3	Adrenocorticotropin-independent Cushing's syndrome in pregnancy related to overexpression of adrenal luteinizing hormone/human chori onic gonadotropin receptors. (19636197)	Rask E.... Rao C.V.	2009	LHCGR
4	Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment. (19390321)	Mazzuco T.L.... Lacroix A.	2009	POMC
5	Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. (19411818)	Erem C.... Onder Ersoz H.	2009	SERPINE1, TFPI
6	Iatrogenic Cushing's syndrome, diabetes mellitus and secondary adrenal failure in a human immunodeficiency virus patient treated wi th ritonavir boosted atazanavir and fluticasone (19419710)	Collet-Gaudillat C.... Beressi J.P.	2009	CYP3A4
7	Mineralocorticoid and glucocorticoid receptors stimul ate epithelial sodium channel activity in a mouse model of Cushing syndrome. (19635986)	Bailey M.A.... Kenyon C.J.	2009	NR3C1
8	Hypertrophic remodeling of subcutaneous small resista nce arteries in patients with Cushing's syndrome. (19864447)	Rizzoni D.... Rosei E.A.	2009	PTGS1, NOS3
9	Diagnosis by serendipity: Cushing syndrome attributable to cortisol-producing adrenal adenoma as the initial manifestation of multiple endocrine neoplasia type 1 due to a rare splicing site MEN1 gene mutation. (18753104)	Alzahrani A.S.... Amin T.	2008	MEN1, GAST
10	Dual bronchial carcinoids and Cushing's syndrome with a paradoxical response to dexamethasone and a false positive outcome of inferior petrosal sinus sampling. (18625689)	Burman P.... Sundin A.	2008	CRH
11	AMP-activated protein kinase mediates glucocorticoid- induced metabolic changes: a novel mechanism in Cushing's syndrome. (18198220)	Christ-Crain M.... Korbonits M.	2008	PRKAA2
12	Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma. (19095601)	Lee J.M.... Fisher N.D.	2008	POMC
13	Pharmacological management of Cushing's syndrome: an update. (18209872)	Dang C.N.... Trainer P.	2007	SST
14	Serum adiponectin and leptin in a patient with Cushing's syndrome before and after adrenalectomy. (17409602)	Ashizawa N.... Yano K.	2007	LEP
15	Editorial: The dexamethasone-suppressed corticotropin -releasing hormone test for the diagnosis of Cushing's syndrome: what have we l earned in 14 years? (17682087)	Nieman L.	2007	CRH
16	The value of corticotropin-releasing hormone (CRH) test for differential diagnosis of Cushing's syndrome (17503565)	PeneziA8 Z.... DrezgiA8 M.	2007	CRH
17	Bilateral adrenalectomy for ectopic Cushing's syndrome-discussions on technique and indication. (16467980)	Hellman P.... AkerstrAPm G.	2006	CRH
18	Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. (16670165)	Martin N.M.... Meeran K.	2006	CRH
19	Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. (15741255)	Matyakhina L.... Stratakis C.A.	2005	FH
20	Spindle cell pancreatic endocrine tumor associated with Cushing's syndrome. (16199900)	Chetty R.... Serra S.	2005	SYP
21	Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. (16260420)	Barzon L.... PalA^ G.	2005	INHA
22	Severe hypertension secondary to renal artery stenosi s and Cushing's syndrome. (15900383)	Alzahrani A.S.... Kanaan I.	2005	POMC
23	Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. (15012619)	Fallo F.... Vettor R.	2004	ADIPOQ
24	Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome. (15009001)	Krsek M.... Murphy L.J.	2004	RETN
25	Characteristics of Cushing's syndrome in Taiwanese. (12874666)	Su D.H.... Huang T.S.	2003	POMC
26	Intraadrenal adrenocorticotropin production in a case of bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. (12843140)	Lefebvre H.... Kuhn J.M.	2003	POMC
27	The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. (11932296)	Tsagarakis S.... Thalassinos N.	2002	AVPR2, AVPR1B
28	Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. (12390331)	Francucci C.M.... Mantero F.	2002	SLPI, BGLAP
29	Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. (12381548)	Torpy D.J.... Nieman L.K.	2002	POMC
30	Expression of ACTH receptor pathway genes in GIP-dependent Cushing's syndrome (CS). (12530693)	Antonini S.R.... Lacroix A.	2002	GIP
31	Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses. (12566947)	Leal-Cerro A.... Casanueva F.F.	2002	POMC, GHRL, GH1
32	The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal. (11380490)	Pecori Giraldi F.... Cavagnini F.	2001	CRH
33	Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. (11158012)	Tsagarakis S.... Thalassinos N.	2001	GIPR
34	Importance of the CRH (corticotropin releasing hormone) test in the differential diagnosis of Cushing's syndrome (11729609)	KorsiA8 M.... AganoviA8 I.	2001	CRH
35	Subclinical Cushing's syndrome in patients with adren al incidentaloma: clinical and biochemical features. (10770179)	Rossi R.... Lombardi G.	2000	POMC
36	Decreased ligand affinity rather than glucocorticoid receptor down-regulation in patients with endogenous Cushing's syndrome. (10802524)	Huizenga N.A.... Lamberts S.W.	2000	NR3C1
37	Enhanced Na+/H+ exchange in Cushing's syndrome reflects functional hypermineralocorticoidism. (9794723)	Koren W.... Postnov Y.V.	1998	POMC, NR3C2
38	Cushing's syndrome due to unilateral adrenocortical h yperplasia. (9630199)	Otsuka F.... Makino H.	1998	POMC, CRH
39	Gastric inhibitory polypeptide (GIP) stimulates cortisol secretion, cAMP production and DNA synthesis in an adrenal adenoma responsible for food-dependent Cushing's syndrome. (9888586)	Chabre O.... Defaye G.	1998	GCG
40	Aberrant expression of the GIP (Gastric Inhibitory Polypeptide) receptor in an adrenal cortical adenoma responsible for a case of food-dependent Cushing's syndrome (10333644)	Luton J.P.... Bertagna X.	1998	GIPR
41	A prospective study of psychiatric and psychological aspects of Cushing's syndrome. (9039337)	Kelly W.F.... Faragher B.	1996	GH1
42	Metastatic pancreatic neuroendocrine carcinoma causing Cushing's syndrome. ACTH secretion by metastases 3 years after resection of nonfunctioning primary cancer. (8807366)	Zhu L.... Howard J.M.	1996	GAST
43	Decreased delta-sleep and plasma delta-sleep-inducing peptide in patients with Cushing syndrome. (7700506)	Friedman T.C.... Chrousos G.P.	1994	TSC22D3
44	Naloxone stimulation of ACTH secretion during petrosal sinus sampling in Cushing's syndrome. (8391944)	Torpy D.J.... Topliss D.J.	1993	POMC, CRH
45	Gastric inhibitory polypeptide-dependent cortisol hyp ersecretion--a new cause of Cushing's syndrome. (1325608)	Lacroix A.... Taillefer R.	1992	POMC, SST
46	Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. (1597149)	Stenzel-Poore M.P.... Vale W.	1992	CRH
47	Cushing's syndrome due to primary pigmented nodular a drenocortical disease with cardiac myxomas and mucocutaneous lentigines. (1600314)	Ichiba Y.... Tanizaki M.	1992	POMC
48	Primary thymic carcinoid with Cushing's syndrome. (1372458)	Wollensak G.... Schaefer H.E.	1992	KITLG, SYP
49	Forty-one cases of Cushing's syndrome: a comparison between Cushing's syndrome (adrenal adenoma) and Cushing's disease (adrenal hyperplasia) (1633931)	Komiya I.... Yamada T.	1992	PRL
50	Cushing's syndrome: new variants and association with empty sella syndrome. (2246674)	Mancini A.... De Marinis L.	1990	PRL

Genes related to cushing's syndrome according to GeneCards:

(show top 50)    (show all 121)

id	Symbol	Description	Score	GeneCards Section Context
1	GIPR	gastric inhibitory polypeptide receptor	11.0	Publications
2	CRH	corticotropin releasing hormone	11.0	Publications
3	POMC	proopiomelanocortin	11.0	Publications
4	GIP	gastric inhibitory polypeptide	11.0	Publications
5	SULT2A1	sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1	11.0	Publications
6	HSD11B1	hydroxysteroid (11-beta) dehydrogenase 1	11.0	Publications
7	CRHBP	corticotropin releasing hormone binding protein	11.0
8	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha	11.0	Publications
9	GNAS	GNAS complex locus	11.0	Publications
10	HSD11B2	hydroxysteroid (11-beta) dehydrogenase 2	11.0	Publications
11	CYP11B1	cytochrome P450, family 11, subfamily B, polypeptide 1	11.0	Publications
12	SST	somatostatin	11.0	Publications
13	TRH	thyrotropin-releasing hormone	11.0	Publications
14	CYP21A2	cytochrome P450, family 21, subfamily A, polypeptide 2	11.0	Publications
15	NR3C1	nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)	11.0	Publications
16	GHRH	growth hormone releasing hormone	11.0	Publications
17	PRL	prolactin	11.0	Publications
18	CYP11B2	cytochrome P450, family 11, subfamily B, polypeptide 2	11.0
19	CALCA	calcitonin-related polypeptide alpha	11.0	Publications
20	REN	renin	11.0	Publications
21	PDE11A	phosphodiesterase 11A	11.0	Publications
22	CNC	Carney complex, multiple neoplasia and lentiginosis	11.0	Publications
23	HSD3BP4	hydroxy-delta-5-steroid dehydrogenase, 3 beta, pseudogene 4	11.0	Publications
24	AVPR1B	arginine vasopressin receptor 1B	11.0	Publications
25	NR2F1	nuclear receptor subfamily 2, group F, member 1	11.0	Publications
26	AVPR2	arginine vasopressin receptor 2	11.0	Publications
27	LHCGR	luteinizing hormone/choriogonadotropin receptor	11.0	Publications
28	HSD17B6	hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse)	11.0
29	GHSR	growth hormone secretagogue receptor	11.0	Publications
30	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
31	CYB5A	cytochrome b5 type A (microsomal)	11.0	Publications
32	SYP	synaptophysin	11.0	Publications
33	MC2R	melanocortin 2 receptor (adrenocorticotropic hormone)	11.0	Publications
34	PDE8B	phosphodiesterase 8B	11.0	Publications
35	NR0B1	nuclear receptor subfamily 0, group B, member 1	11.0
36	CYP17A1	cytochrome P450, family 17, subfamily A, polypeptide 1	11.0	Publications
37	CYP11A1	cytochrome P450, family 11, subfamily A, polypeptide 1	11.0	Publications
38	RETN	resistin	11.0	Publications
39	MEN1	multiple endocrine neoplasia I	11.0	Publications
40	AGTR2	angiotensin II receptor, type 2	11.0
41	SP3	Sp3 transcription factor	11.0	Publications
42	INHA	inhibin, alpha	11.0	Publications
43	LSL	Leptin, serum levels of	11.0	Publications
44	SERPINA6	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6	11.0	Publications
45	POR	P450 (cytochrome) oxidoreductase	11.0	Publications
46	LEP	leptin	11.0	Publications
47	IGFBP1	insulin-like growth factor binding protein 1	11.0	Publications
48	BGLAP	bone gamma-carboxyglutamate (gla) protein	11.0	Publications
49	CYP3A4	cytochrome P450, family 3, subfamily A, polypeptide 4	11.0	Publications
50	TNFRSF11B	tumor necrosis factor receptor superfamily, member 11b	11.0	Publications

Pathways related to cushing's syndrome according to GeneDecks:

(show top 50)    (show all 84)

id	Pathway	Score	Top Affiliating Genes
1	G alpha (s) signalling events38	10.6	POMC, PDE8B, GIP, CGA, AVPR2, PDE11A
2	Breast Cancer Regulation by Stathmin136	10.6	ADCY1, GHRH, FGF21, FGF19
3	Class B/2 (Secretin family receptors)38	10.6	CALCA, GHRH, CRH, ADM, GNAS, GIPR
4	Adenylate cyclase-activating neuropeptides10	10.6	MC3R, ADCY1, AGRP, AVPR2, CALCA, GCG
5	Selected targets of CREB110	10.5	CRH, NR4A2, REN, MC2R, INS, GCG
6	ACE Inhibitor Pathway, Pharmacodynamics34	10.3	AGTR2, NR3C2
7	Adipocytokine signaling pathway20	10.3	AGRP, LEP, PRKAA2, PRKAB1, ADIPOQ, POMC
8	Neuroactive ligand-receptor interaction20	10.1	HTR7, NR3C1, AGTR2, LHCGR, LEP, TSHR
9	Development Role of Activin A in cell differentiation and proliferation10	10.1	CDKN1B, CGA, SP1, CYP11A1, LHCGR, GNAS
10	Development_Role of Activin A in cell differentiation and proliferation41	10.1	ADCY1, CGA, PBX1, LHCGR, CDKN1B, GNAS
11	Adipocytokines & Insulin Signaling37	10.1	PRKAB1, PRKAA2, INS, ADIPOQ, RETN, LEP
12	Telomerase Components in Cell Signaling36	10.0	GNRH1, GHRH, IGF1, FGF21, FGF19, KITLG
13	CREB Pathway36	9.8	IL2RA, IGF2, IGF1, GNRH1, KITLG, GH1
14	Transcription_Role of VDR in regulation of genes involved in osteoporosis41	9.7	TNFSF11, NR3C1, CYP19A1, BGLAP, CGA, IL6
15	Transcription Role of VDR in regulation of genes involved in osteoporosis10	9.7	CGA, IL6, IGF1, TNFRSF11B, TNFSF11, CYP3A4
16	Akt Signaling36	9.7	TNFSF11, FGF19, FGF21, IL18, IL2RA, IL6
17	eNOS Signaling36	9.5	GNRH1, FGF21, FGF19, KITLG, CASP3, GH1
18	PPAR Pathway36	9.5	KITLG, IL2RA, IL6, IGF2, IGF1, GH1
19	NF-KappaB (p50-p65) Pathway36	9.4	KITLG, FGF19, IL6, GNRH1, IGF1, GH1
20	mTOR Pathway36	9.3	INS, FGF21, IL6, IGF2, IGF1, GNRH1
21	Nuclear Receptor Activation by Vitamin-A36	9.3	FGF19, PRKAR1A, GHRH, GH1, IGF1, IGF2
22	Renin-Angiotensin Pathway36	9.3	KITLG, REN, GNRH1, FGF19, IGF2, GH1
23	eIF2 Pathway36	9.2	GH1, KITLG, INS, FGF19, FGF21, IL2RA
24	ERK Signaling36	9.2	KITLG, GHRH, TNFSF11, ADCY1, GNRH1, IGF2
25	p70S6K Signaling36	9.1	GH1, INS, FGF21, FGF19, KITLG, IGF2
26	Selected targets of GCR-alpha10	9.1	IL6, IL8, IGFBP1, GHSR, LEP, GHR
27	Activation of PKC through GPCR36	9.1	KITLG, FGF19, FGF21, IL2RA, IL6, IGF2
28	Activation of PKA through GPCR36	8.9	FGF19, PRKAR1A, NOS3, GH1, GNRH1, IGF1
29	Apoptotic Pathways in Synovial Fibroblasts36	8.8	IGF1, KITLG, FGF19, FGF21, IL2RA, IL6
30	ERK5 Signaling36	8.7	KITLG, GHRH, GH1, GNRH1, IGF2, IL2RA
31	Pathways in cancer20	8.6	RET, FGF19, BCL2, FH, FGF21, CASP3
32	Estrogen Pathway36	8.2	NOS3, IGF1, GNRH1, IGF2, GH1, GHRH
33	JNK Pathway36	8.2	TP53, IL2RA, GHRH, IL6, KITLG, FGF21
34	DHA Signaling36	8.1	FGF21, GHRH, GH1, CASP3, GNRH1, IGF1
35	Pancreatic Adenocarcinoma36	7.9	BCL2, CDKN1B, IGF1, FGF21, IGF2, KITLG
36	p53 Mediated Apoptosis36	7.6	IL2RA, IGF2, TP53, FGF21, IGF1, GNRH1
37	TGF-Beta Pathway36	7.6	GH1, GNRH1, IGF1, KITLG, IGF2, IL8
38	Mitochondrial Apoptosis36	7.6	TP53, IGF2, IL2RA, FGF21, KITLG, FGF19
39	Cellular Apoptosis Pathway36	7.6	BCL2, BAX, FGF19, FGF21, IL2RA, IL6
40	MAPK Family Pathway36	7.6	IGF2, IL8, FGF19, IGF1, BCL2, BAX
41	Tec Kinases Signaling36	7.6	IGF1, GNRH1, GH1, GHRH, IGF2, IL8
42	Antioxidant Action of Vitamin-C36	7.5	KITLG, BCL2, FGF19, IL8, PRKAR1A, TNFSF11
43	Molecular Mechanisms of Cancer36	7.4	KITLG, TP53, ADCY1, TNFSF11, GH1, BCL2
44	JAK-STAT Pathway36	7.3	FGF19, FGF21, BAX, BCL2, GHR, GH1
45	PAK Pathway36	7.3	IL8, GNRH1, IL2RA, IL18, FGF21, FGF19
46	p38 Signaling36	6.6	GNRH1, IL8, IL2RA, IL18, FGF21, FGF19
47	Steroid hormone biosynthesis20	INF	HSD3B2, HSD11B2, HSD17B6, , HSD11B1, CYP11B2
48	Androstenedione and testosterone biosynthesis and metabolism p.141	INF	, HSD3B2, SULT2A1, CYP17A1, CYP3A4
49	Androstenedione and testosterone biosynthesis and metabolism p.110	INF	, HSD3B2, SULT2A1, CYP3A4, CYP17A1
50	Metabolism of lipids and lipoproteins38	INF	PTGS1, CYP11B2, HSD11B1, HSD3B2, , LPL

Compounds related to cushing's syndrome according to GeneDecks:

(show top 50)    (show all 545)

id	Compound	Score	Top Affiliating Genes
1	cyclophosphamide32 34 9 9	13.8	F9
2	naloxone32 34 9 9	13.5	LEP, CGA, GNRH1, GH1, GHRH, GHRL
3	11 deoxycortisol32	10.4	REN, SERPINA6, CGA, CYP11B2, CYP11B1, CYP17A1
4	pioglitazone32 9 9	12.4	RETN, GCG, LPL, LEP, INS, IGFBP1
5	acipimox32	10.3	GCG, LEP, INS, IGF1, GH1, GHRH
6	2-deoxyglucose32	10.2	INS, IGF2, IGF1, CALCA, GHRL, AGRP
7	acth 1-2432	10.2	SERPINA6, MC2R, IGF2, CYP11A1, CYP17A1, CYP21A2
8	spironolactone32 42 34 9 9	14.0	REN, SERPINA7, SERPINE1, GNRH1, HSD11B2, CYP11B2
9	sodium32 18	10.8	REN, RETN, AVPR2, MC2R, ENO2, HSD11B2
10	c-peptide32	9.8	RETN, GCG, LEP, IGF2, GIP, GHR
11	hexarelin32	9.7	PBX1, IGFBP3, IGF1, GH1, GHR, GHRH
12	ghrp32	9.6	PBX1, IGFBP3, IGF1, GH1, GHR, GHRH
13	flutamide32 9 9	11.6	LHCGR, CHGA, CGA, ENO2, GNRH1, TNFRSF11B
14	vitamin a32 9 18 9	12.6	RET, RETN, VWF, SERPINA7, SERPINA6, LPL
15	corticosterone32 18	10.5	GCG, SERPINA7, SERPINA6, BGLAP, LHCGR, AVPR1B
16	pge232	9.4	REN, LHCGR, CGA, IL1RN, GNAS, HSD3BP4
17	histidine32	9.3	KITLG, SERPINA7, LHCGR, CHGA, S100B, FHIT
18	h2o232	9.2	KITLG, VWF, BGLAP, LEP, CGA, IL18
19	p00232	9.2	RETN, LEP, CHGA, MKI67, IL18, IL1RN
20	triiodothyronine32	9.1	SERPINA7, SERPINA6, LEP, CGA, IGFBP1, IGF2
21	buserelin32 9 9	11.1	LHCGR, CGA, IGFBP1, IGFBP3, IGF1, GNRH1
22	progestins32	9.1	SERPINA7, SERPINA6, MKI67, IGFBP1, IGF2, IGFBP3
23	epinephrine32 9 18 9	12.1	REN, KITLG, GCG, LEP, CHGA, CGA
24	prostaglandin32	9.0	REN, KITLG, CGA, IL1RN, IL6, ENO2
25	octreotide32 42 9 9	12.0	GCG, CHGA, MKI67, INS, ENO2, IGFBP1
26	glycerol32 9 18 9	11.9	VWF, PCNA, GCG, LPL, LEP, CD36
27	acetylcholine32 9 18 9	11.9	VWF, GCG, LPL, LEP, CHGA, S100B
28	losartan32 34 9 9	11.8	REN, VWF, PCNA, SERPINE1, LEP, CD36
29	gnrh32	8.8	KITLG, GCG, SERPINE1, PBX1, LHCGR, LEP
30	dhea32	8.5	RETN, SERPINA6, LEP, INS, MC2R, IGFBP1
31	ly29400232	8.4	RET, RETN, GCG, LEP, CDKN1B, IL18
32	chloramphenicol32 9 9	10.3	SERPINA7, SERPINE1, LPL, CHGA, MUC1, S100B
33	raloxifene32 9 9	10.3	VWF, SERPINA7, SERPINE1, BGLAP, CD36, CDKN1B
34	mifepristone32 42 9 9	11.2	SERPINA6, MUC1, BAX, CGA, MKI67, IL8
35	thyroxine32 18	9.0	REN, RETN, VWF, PCNA, SERPINA7, SERPINA6
36	cysteine32	7.9	PCNA, GCG, SERPINA6, BGLAP, MUC1, S100B
37	rosiglitazone32 9 18 9	10.9	RETN, SERPINE1, LPL, CD36, INS, IL18
38	celecoxib32 42 34 9 18 9	12.8	REN, PCNA, BCL2, BAX, CDKN1B, MKI67
39	ribonucleic acid32	7.7	RET, KITLG, SERPINA7, SERPINA6, LHCGR, CHGA
40	norepinephrine32 9 18 9	10.2	REN, RETN, KITLG, VWF, GCG, LPL
41	hydrocortisone32 9 9	9.1	REN, KITLG, SERPINA6, PBX1, BGLAP, MUC1
42	indomethacin32 9 9	9.0	REN, PCNA, GCG, LPL, LEP, CGA
43	creatinine32	7.0	REN, RETN, KITLG, VWF, PCNA, GCG
44	pd 98,05932	6.6	RET, KITLG, GCG, SERPINE1, BCL2, LEP
45	alanine32	6.1	RET, RETN, KITLG, VWF, PCNA, GCG
46	lactate32	5.4	KITLG, VWF, PCNA, GCG, LPL, CHGA
47	actinomycin d32	5.1	RETN, KITLG, SERPINE1, BCL2, MUC1, BAX
48	3beta-hydroxysteroid32	INF	LHCGR, CGA, INHA, MC2R, IGF2, HSD11B2
49	progesterone32 42 9 18 9	INF	PCNA, SERPINA7, SERPINA6, PBX1, BCL2, LHCGR
50	cholesterol32 9 18 9	INF	REN, RETN, KITLG, VWF, SERPINA7, SERPINA6

Cellular components related to cushing's syndrome according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	secretory granule	GO:030141	9.7	POMC, PLAT, CRHBP, TRH, GHRL, GIP
2	endoplasmic reticulum	GO:005783	8.4	TP53, CYP17A1, CYP19A1, CRHBP, POR, HSD3B2
3	extracellular space	GO:005615	6.3	LPL, BGLAP, LHCGR, LEP, INS, IL18
4	extracellular region	GO:005576	5.4	PRL, POMC, NPY, SLPI, ADM, ADIPOQ

Biological processes related to cushing's syndrome according to GeneDecks:

(show top 50)    (show all 64)

id	Name	GO ID	Score	Top Affiliating Genes
1	activation of adenylate cyclase activity	GO:007190	10.8	GIPR, CALCA, GNAS, AVPR2, LHCGR
2	hormone-mediated signaling pathway	GO:009755	10.7	AGRP, CRHBP, TRH, GHSR, GHRL, GHR
3	adult feeding behavior	GO:008343	10.7	NPY, AGRP, GHSR, GHRL, LEP
4	response to food	GO:032094	10.7	GHSR, GHRH, GHR, HSD11B2
5	positive regulation of appetite	GO:032100	10.6	NPY, GHSR, GHRL
6	regulation of insulin secretion	GO:050796	10.6	PRKAR1A, SSTR5, GIP, GNAS, INS, LEP
7	positive regulation of cAMP biosynthetic process	GO:030819	10.6	ADM, GHRH, CALCA, MC3R, MC2R, GCG
8	adrenal gland development	GO:030325	10.6	CRH, NR5A1, NR3C1, NR0B1, CYP19A1, CYP17A1
9	cellular response to potassium ion	GO:035865	10.6	CRHBP, CYP11B1, CYP11B2
10	adenylate cyclase-modulating G-protein coupled receptor signaling pathway	GO:007188	10.6	MC3R, AVPR2, AVPR1B, LHCGR, GCG
11	positive regulation of glucose import	GO:046326	10.5	ADIPOQ, IGF1, FGF21, FGF19, INS
12	energy reserve metabolic process	GO:006112	10.5	ADCY1, PRKAR1A, PRKAA2, GIP, GNAS, INS
13	regulation of blood pressure	GO:008217	10.5	POMC, AGTR2, NOS3, CYP11B1, PTGS1, CALCA
14	phthalate metabolic process	GO:018963	10.4	CYP19A1, CYP17A1, CYP11A1
15	positive regulation of vasodilation	GO:045909	10.4	ADM, AGTR2, NOS3, CALCA, INS
16	feeding behavior	GO:007631	10.4	GCG, CALCA, CRH, AGRP, NPY
17	biphenyl metabolic process	GO:018879	10.4	CYP19A1, CYP17A1, CYP11A1
18	xenobiotic metabolic process	GO:006805	10.4	CYP21A2, CYP19A1, CYP17A1, CYP11B1, CYP11A1, CYP3A4
19	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:007187	10.4	NPY, TSHR, SSTR5, HTR7, HTR4, MC3R
20	positive regulation of insulin-like growth factor receptor signaling pathway	GO:043568	10.4	GHSR, GHRH, GH1, IGF1, IGFBP3
21	adenylate cyclase-activating G-protein coupled receptor signaling pathway	GO:007189	10.2	ADCY1, TSHR, GHRH, GIPR, CALCA
22	lung development	GO:030324	10.2	NOS3, CRH, NR3C1, SP3, SP1, HSD11B1
23	glucose homeostasis	GO:042593	10.1	ADIPOQ, PRKAA2, SSTR5, CYP11B1, INS, SERPINE1
24	dibenzo-p-dioxin metabolic process	GO:018894	9.9	CYP19A1, CYP17A1, CYP11A1
25	cell-cell signaling	GO:007267	9.9	SST, NR5A1, TSHR, POMC, PGR, ADM
26	transcription initiation from RNA polymerase II promoter	GO:006367	9.9	PGR, NR5A1, NR4A2, NR3C2, NR3C1, NR2F1
27	response to corticosterone stimulus	GO:051412	9.9	NR3C1, CYP11A1, PTGS1, TRH, BCL2, SERPINA7
28	female pregnancy	GO:007565	9.8	ADM, PRL, CRHBP, CRH, GIP, HSD11B2
29	G-protein coupled receptor signaling pathway	GO:007186	9.7	GHSR, SST, SSTR5, AGTR2, TSHR, GAST
30	positive regulation of multicellular organism growth	GO:040018	9.7	TSHR, GHSR, GHRL, GHRH, GHR, GH1
31	response to estrogen stimulus	GO:043627	9.6	CYP11A1, TNFRSF11B, GHRL, BCL2, BGLAP, SERPINE1
32	male gonad development	GO:008584	9.6	NR5A1, NR0B1, CYP19A1, INHA, LHCGR, BCL2
33	response to glucocorticoid stimulus	GO:051384	9.2	ADIPOQ, ADM, PLAT, GHR, HSD11B2, IL6
34	ovarian follicle development	GO:001541	9.2	INHA, BAX, LHCGR, BCL2, KITLG
35	response to gamma radiation	GO:010332	9.1	BCL2, BAX, MEN1, TP53, CYP11A1
36	positive regulation of MAPK cascade	GO:043410	9.1	IGF1, IGFBP3, IGF2, IL6, INS, CD36
37	response to hypoxia	GO:001666	9.1	ADIPOQ, ADM, NOS3, PLAT, TRH, HSD11B2
38	response to drug	GO:042493	9.0	TNFRSF11B, CYP11A1, CYP17A1, CYP19A1, SST, NOS3
39	positive regulation of cell proliferation	GO:008284	9.0	IGF2, IGF1, HTR4, GHRH, TSHR, ADM
40	signal transduction	GO:007165	8.9	CRHBP, CRH, NR4A2, NR3C2, NR3C1, PRKAA2
41	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	8.8	GH1, GHR, TP53, ADIPOQ, IGF1, IGF2
42	blood coagulation	GO:007596	8.6	TFPI, NOS3, PLAT, TP53, GNAS, F9
43	negative regulation of cell proliferation	GO:008285	8.0	TP53, SST, SSTR5, NOS3, ADM, GNRH1
44	negative regulation of apoptotic process	GO:043066	7.7	POR, PRKAA2, TP53, GHRL, CASP3, IL6
45	steroid metabolic process	GO:008202	INF	CYP21A2, CYP19A1, CYP17A1, CYP11B1, CYP11A1, CYP3A4
46	glucocorticoid biosynthetic process	GO:006704	INF	HSD11B2, CRH, CYP21A2, CYP17A1, CYP11B1, HSD11B1
47	small molecule metabolic process	GO:044281	INF	CYP11B2, CYP3A4, CYP11A1, CYP11B1, CYP17A1, CYP19A1
48	androgen biosynthetic process	GO:006702	INF	CYP17A1, HSD3B2, , HSD17B6
49	steroid biosynthetic process	GO:006694	INF	NR0B1, CYP19A1, CYP17A1, HSD3B2, , PBX1
50	mineralocorticoid biosynthetic process	GO:006705	INF	CYP21A2, CYP11B1, CYP11B2, HSD3B2,

Molecular functions related to cushing's syndrome according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	peptide hormone binding	GO:017046	10.5	GHSR, GHR, GIPR, MC3R, AVPR1B, LHCGR
2	electron carrier activity	GO:009055	10.4	POR, CYP21A2, CYP19A1, CYP17A1, CYP11B1, CYP11A1
3	steroid binding	GO:005496	10.4	PGR, NR3C2, NR3C1, CYP21A2, CYP3A4, HSD11B2
4	iron ion binding	GO:005506	10.1	POR, NOS3, CYP21A2, CYP19A1, CYP17A1, CYP11B1
5	neuropeptide hormone activity	GO:005184	10.1	NPY, AGRP, CRH, TRH
6	insulin-like growth factor receptor binding	GO:005159	10.1	IGF1, IGF2, INS, REN
7	double-stranded DNA binding	GO:003690	10.1	NR5A1, NR3C1, NR0B1, SP3, SP1, MEN1
8	steroid hormone receptor activity	GO:003707	10.1	PGR, NR5A1, NR4A2, NR3C2, NR2F1, NR0B1
9	heme binding	GO:020037	10.1	NOS3, CYP21A2, CYP19A1, CYP17A1, CYP11B1, CYP11A1
10	hormone activity	GO:005179	9.8	RETN, GH1, SST, CRH, PRL, POMC
11	receptor binding	GO:005102	9.5	AGRP, POMC, NPY, PGR, ADM, ADIPOQ
12	growth factor activity	GO:008083	9.3	GH1, IGF1, IGF2, IL6, FGF21, FGF19
13	protease binding	GO:002020	8.8	SERPINE1, BCL2, INS, TP53
14	protein homodimerization activity	GO:042803	8.6	ADIPOQ, SHBG, NR3C1, NR0B1, SP1, GHR
15	protein binding	GO:005515	2.9	NR0B1, NR2F1, NR3C1, NR3C2, NR4A2, SP3